SXTP vs. EDSA, BFRG, SYBX, RLYB, ALVR, FLGC, IMNN, TXMD, ME, and ASBP
Should you be buying 60 Degrees Pharmaceuticals stock or one of its competitors? The main competitors of 60 Degrees Pharmaceuticals include Edesa Biotech (EDSA), Bullfrog AI (BFRG), Synlogic (SYBX), Rallybio (RLYB), AlloVir (ALVR), Flora Growth (FLGC), Imunon (IMNN), TherapeuticsMD (TXMD), 23andMe (ME), and Aspire Biopharma (ASBP). These companies are all part of the "pharmaceutical products" industry.
60 Degrees Pharmaceuticals vs. Its Competitors
Edesa Biotech (NASDAQ:EDSA) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.
5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 22.6% of Edesa Biotech shares are held by insiders. Comparatively, 10.3% of 60 Degrees Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Edesa Biotech currently has a consensus price target of $5.00, indicating a potential upside of 139.23%. 60 Degrees Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 177.78%. Given 60 Degrees Pharmaceuticals' higher possible upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Edesa Biotech.
In the previous week, Edesa Biotech had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 2 mentions for Edesa Biotech and 1 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat Edesa Biotech's score of 1.28 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.
Edesa Biotech has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -1,947.30%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Edesa Biotech's return on equity.
Edesa Biotech has higher earnings, but lower revenue than 60 Degrees Pharmaceuticals. Edesa Biotech is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Edesa Biotech has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.78, meaning that its stock price is 178% more volatile than the S&P 500.
Summary
Edesa Biotech beats 60 Degrees Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get 60 Degrees Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
60 Degrees Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SXTP) was last updated on 7/11/2025 by MarketBeat.com Staff
Free SXTP Stock Alerts